Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexidartinib and sirolimus in unresectable sarcoma and MPNST
NCT02584647Phase 2Terminated
- Start
- Nov 2015
- Primary completion
- Jul 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pexidartinib in sarcoma, malignant peripheral nerve sheath tumor (MPNST). Started Nov 2015; status: terminated.
02
Drugs
pexidartinib
03
Conditions
sarcomamalignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT02584647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02584647.